Angarus Therapeutics Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Out of Business

  • Latest Deal Type
  • Out of Business

Angarus Therapeutics General Information

Description

Developer of immuno-oncology therapies designed to respond to the urgent needs of cancer treatment. The company's therapies develop checkpoint blockers on the innate immunity pathway that enhance the killing power of tumor-infiltrating lymphocytes and produce durable responses in a small fraction, enabling doctors to help patients by targeting immunological aspects of the tumor microenvironment.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • 321 Dedalera Drive
  • Portola Valley, CA 94028
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 321 Dedalera Drive
  • Portola Valley, CA 94028
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Angarus Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Out of Business Completed Out of Business
3. Secondary Transaction - Private Completed Clinical Trials - Phase 1
2. Early Stage VC (Series A) 22-Jun-2021 $11.3M $12.3M Completed Clinical Trials - Phase 1
1. Seed Round $1M $1M Completed Startup
To view Angarus Therapeutics’s complete valuation and funding history, request access »

Angarus Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
Seed
To view Angarus Therapeutics’s complete cap table history, request access »

Angarus Therapeutics Patents

Angarus Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4422639-A1 Enpp1 inhibitors as inhibitors of metastasis Pending 29-Oct-2021
EP-4422639-A4 Enpp1 inhibitors as inhibitors of metastasis Pending 29-Oct-2021
WO-2023077083-A1 Enpp1 inhibitors as inhibitors of metastasis Inactive 29-Oct-2021
EP-4395786-A1 Enpp1 inhibitors and immune cells expressing chimeric antigen receptors Pending 03-Sep-2021
EP-4395786-A4 Enpp1 inhibitors and immune cells expressing chimeric antigen receptors Pending 03-Sep-2021 A61K40/42
To view Angarus Therapeutics’s complete patent history, request access »

Angarus Therapeutics FAQs

  • When was Angarus Therapeutics founded?

    Angarus Therapeutics was founded in 2018.

  • Where is Angarus Therapeutics headquartered?

    Angarus Therapeutics is headquartered in Portola Valley, CA.

  • What industry is Angarus Therapeutics in?

    Angarus Therapeutics’s primary industry is Drug Discovery.

  • Is Angarus Therapeutics a private or public company?

    Angarus Therapeutics is a Private company.

  • What is Angarus Therapeutics’s current revenue?

    The current revenue for Angarus Therapeutics is .

  • How much funding has Angarus Therapeutics raised over time?

    Angarus Therapeutics has raised $12.3M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process